CTLA4 and neoplasm: We systematically compared different immunotherapies that lead to tumor rejection, including NeoAg cancer vaccines, anti-CTLA-4, anti-PD-1, and anti-CTLA-4 + anti-PD-1 ICT using mouse melanoma models expressing defined NeoAgs.